IUD Insertion (IUCD) — Cost, Top Hospitals & Success Rates | MyMedicPlus

An intrauterine contraceptive device (IUCD or IUD) is a small, T-shaped device inserted through the cervix into the uterine cavity by a trained healthcare provider. IUDs are among the most effective, long-acting reversible contraceptive (LARC) methods available, with failure rates below 1% per year — comparable to surgical sterilisation — while remaining fully reversible upon removal.

Two fundamentally different classes of IUD are available:

• Copper IUD (Cu-IUD): Contains no hormones. Copper ions released within the uterus are spermicidal and create a hostile environment for fertilisation. The most widely used copper device globally is the Paragard T380A, licensed for up to 10 years of use in the USA, and among the longest-lasting reversible contraceptives. The copper IUD is also uniquely effective as emergency contraception when inserted within 5 days of unprotected intercourse, with a failure rate of less than 0.1%.
• Levonorgestrel intrauterine system (LNG-IUS): Releases a low daily dose of levonorgestrel (a progestin) directly into the uterine cavity, acting primarily by thickening cervical mucus to prevent sperm penetration, suppressing endometrial proliferation, and in higher-dose devices, partially suppressing ovulation. Available in multiple dose sizes for different clinical needs.

The procedure of IUD insertion involves bimanual pelvic examination to assess uterine size and position, cervical sounding to measure uterine depth, and passage of the folded IUD through the cervical canal into the fundus using an insertion tube. The retrieval strings are trimmed to protrude 2-3 cm from the cervical os, allowing the patient and clinician to confirm correct placement.

Insertion can be performed at any point in the menstrual cycle if pregnancy is reasonably excluded, and is also appropriate immediately post-partum (within 10 minutes of placental delivery) or post-abortion. Nulliparous women can successfully use IUDs, although insertion may be more uncomfortable and expulsion rates are marginally higher compared to parous women.

IUD insertion is indicated for several contraceptive and non-contraceptive purposes:

Contraceptive Indications

• Long-acting reversible contraception (LARC): The primary indication for both copper and hormonal IUDs. Suitable for women who desire effective contraception for 3-10 years without the need for daily compliance (pills) or regular clinic visits (injections, implants). Recommended by NICE (UK) and CDC (USA) as a first-line contraceptive for most women, including adolescents and nulliparous women.
• Emergency contraception: The copper IUD is the most effective post-coital contraceptive available. Inserted within 120 hours (5 days) of unprotected intercourse, it prevents pregnancy in over 99.9% of cases — significantly more effective than oral emergency contraceptive pills (levonorgestrel EC: ~85% effective; ulipristal acetate: ~98% effective within 5 days). The copper IUD can be retained for ongoing contraception if desired.
• Perimenopause contraception: The Mirena 52 mg LNG-IUS is often preferred for perimenopausal women as it provides contraception, reduces menstrual bleeding, and can serve as the progestogen component of hormone replacement therapy (HRT) when combined with oestrogen.

Non-Contraceptive (Therapeutic) Indications

• Heavy menstrual bleeding (menorrhagia): The 52 mg LNG-IUS (Mirena) is licensed and highly effective for heavy menstrual bleeding. It reduces menstrual blood loss by 70-95% within 3-6 months, achieving amenorrhoea in 30-50% of users by 12 months. Recommended as a first-line medical treatment for menorrhagia before surgical options.
• Dysmenorrhoea (painful periods): The LNG-IUS substantially reduces menstrual pain by suppressing endometrial prostaglandin production.
• Endometriosis: Off-label use of the LNG-IUS for management of endometriosis-related pain is supported by evidence and clinical guidelines, particularly as maintenance therapy after surgical excision.
• Endometrial protection during HRT: The Mirena LNG-IUS is used as the progestogenic component in combined HRT regimens for perimenopausal and menopausal women, providing endometrial protection without systemic progestogen exposure.
• Management of adenomyosis: The LNG-IUS reduces pain and bleeding associated with adenomyosis in selected patients.

Eligibility is assessed using the WHO Medical Eligibility Criteria for Contraceptive Use (WHO MEC), a globally adopted framework classifying conditions as MEC 1 (no restriction — use freely), MEC 2 (advantages outweigh risks), MEC 3 (risks outweigh advantages — use with caution), or MEC 4 (absolute contraindication — do not use). The UK equivalent is the FSRH UK MEC (UKMEC).

Conditions That Are Not Contraindications (IUDs Are Suitable)

• Nulliparity — younger or childless women are good IUD candidates; insertion is more uncomfortable but device works equally well
• Adolescence — IUDs are recommended for adolescents as effective LARCs
• Breastfeeding — copper IUD and LNG-IUS are safe during lactation; insertion can occur at any time postpartum
• History of ectopic pregnancy (MEC 2 for copper IUD; MEC 3 for LNG-IUS — caution required)
• Diabetes mellitus — copper IUD is MEC 1; LNG-IUS is MEC 2
• Hypertension, migraine with aura, obesity — these conditions often make oestrogen-containing methods less suitable; IUDs are preferred alternatives

Absolute Contraindications (MEC 4)

• Current or recent (within 3 months) pelvic inflammatory disease (PID) or sexually transmitted infection — insertion must be deferred and infection treated first
• Unexplained abnormal uterine bleeding — must be investigated and the cause identified before insertion
• Uterine anomaly distorting the cavity (e.g., large fibroids, significant bicornuate uterus, uterine septum) — prevents correct placement
• Confirmed or suspected pregnancy
• Gestational trophoblastic disease with elevated hCG
• Copper IUD only — Wilson's disease: Copper accumulation disorder; copper IUD is absolutely contraindicated; LNG-IUS is suitable
• Copper allergy
• LNG-IUS only — current breast cancer (MEC 4); personal history of breast cancer is MEC 3 — use with caution

Choosing between copper and hormonal IUDs depends on contraceptive preference, menstrual pattern, medical history, and desired duration of use.

Copper IUD — Paragard T380A

• Mechanism: Copper ions impair sperm motility and viability; create a hostile endometrial environment that prevents implantation if fertilisation occurs; copper in the cervical mucus provides additional barrier
• Duration: Licensed for 10 years in the USA; evidence supports effectiveness for up to 12 years; can be inserted in women aged 40+ and retained until menopause
• Menstrual effect: Increases menstrual flow by 20-50% and worsens dysmenorrhoea — the main reason for discontinuation; NSAIDs mitigate dysmenorrhoea
• Hormonal effect: None — the preferred choice for women who cannot or do not want to use hormonal contraception
• Emergency contraception use: Effective up to 5 days post-unprotected sex; highest efficacy of any emergency contraceptive

Levonorgestrel IUS — Hormonal Devices

• Mirena 52 mg LNG-IUS: Releases 20 mcg levonorgestrel per day initially, declining to 10 mcg/day by year 5. Licensed for 5 years for contraception and menorrhagia treatment; evidence supports 8-year contraceptive use. Causes amenorrhoea in 30-50% of users; significantly reduces menstrual flow in others. The only LNG-IUS licensed for HRT endometrial protection.
• Kyleena 19.5 mg LNG-IUS: Releases 17.5 mcg/day initially, declining to 9.4 mcg/day at end of use. Licensed for 5 years. Smaller frame than Mirena — potentially easier insertion in nulliparous women. Less endometrial suppression than Mirena; periods lighter but amenorrhoea less common.
• Jaydess (Skyla) 13.5 mg LNG-IUS: Releases 14 mcg/day initially, declining to 5 mcg/day at 3 years. Licensed for 3 years. Smallest frame — designed for nulliparous and adolescent patients. Minimal systemic progestogen absorption; periods often lighter but irregular spotting common.

Insertion Technique and Pain Management

The insertion procedure: pelvic examination, cervical tenaculum application (for traction), uterine sounding (measures cavity depth — must be 6-10 cm for safe placement), IUD loading into inserter tube, passage through cervical os to fundus using a 'no-touch' technique, withdrawal of inserter, and string trimming.

Pain management strategies include topical cervical anaesthetic gel (2% lidocaine), oral NSAIDs (ibuprofen 400-800 mg) taken 1 hour before the procedure, and paracervical block in women anticipated to have difficult insertion. The Cochrane systematic review (2019) found insufficient evidence to routinely recommend misoprostol (a cervical ripening agent) for all patients before insertion; it may be considered for nulliparous women or when difficult insertion is anticipated, but causes side effects (cramping, nausea) and requires informed consent.

The IUD offers a combination of effectiveness, convenience, reversibility, and therapeutic benefit that makes it one of the most recommended contraceptive methods globally:

• Exceptional contraceptive efficacy: Typical use failure rate below 1% per year for both copper and hormonal IUDs. This compares favourably to combined oral contraceptive pills (typical use: 7-9% failure rate), condoms (typical use: 13%), and injectable contraceptives (typical use: 4-6%). The distinction between perfect use and typical use rates is minimised with IUDs because no daily action is required.
• Long-acting with no compliance burden: Once inserted, the IUD provides continuous contraception for 3-10 years with no daily pills, weekly patches, or quarterly injections. This is particularly valuable for women with irregular schedules or those who have experienced non-compliance with daily methods.
• Rapidly reversible: Fertility returns within 1-2 menstrual cycles after IUD removal in the majority of women, with no known long-term impact on fertility. This is contrary to persistent myths about IUDs causing infertility.
• Therapeutic benefits of LNG-IUS: Significant reduction in menstrual blood loss (70-95%), making Mirena a first-line non-surgical treatment for menorrhagia and a treatment option for endometriosis, adenomyosis, and dysmenorrhoea.
• Non-oestrogen options: Both copper and hormonal IUDs avoid oestrogen, making them safe for women with contraindications to oestrogen (thromboembolic history, migraine with aura, smokers over 35, hypertension, breast cancer history for copper IUD).
• Cost-effective: Although the upfront cost of device and insertion is higher than oral contraceptives, the cost per year of use over 5-10 years is substantially lower than any other reversible method.
• Postpartum and post-abortion use: IUDs can be inserted immediately post-partum (within 10 minutes of placental delivery) or immediately post-abortion (first or second trimester), providing immediate contraception when motivation and clinical access are high.

IUD insertion is a safe procedure with a well-established risk profile. Most risks are rare, and many are manageable when detected early.

Insertion-Related Risks

• Pain during insertion: Cramping and pain during the procedure are expected. Severity varies widely — some women experience mild discomfort while others require additional pain management. Nulliparous women tend to experience greater discomfort. Pain typically peaks at the moment of sounding and device passage, resolving within minutes to an hour.
• Vasovagal reaction: A small proportion of women (approximately 1-2%) experience a vasovagal episode (lightheadedness, bradycardia, fainting) during or immediately after insertion due to cervical stimulation. Resolved by positioning supine with legs elevated. The procedure area should have facilities to manage this.
• Uterine perforation: The IUD inserter or sound can perforate the uterine wall in approximately 1 in 1,000 insertions. Risk is higher post-partum (particularly breastfeeding women with uterine involution), with inexperienced inserters, and in women with extreme uterine retroversion. Diagnosis by ultrasound; management may require laparoscopic retrieval.

Post-Insertion Complications

• Expulsion: Partial or complete expulsion of the IUD occurs in approximately 3-7% of users in the first year, most commonly in the first 3 months. Risk factors include heavy menstrual bleeding, younger age, nulliparity, and immediate post-partum insertion. Women should check for strings monthly and report any change.
• Pelvic inflammatory disease (PID): The most critical infection risk is in the first 20 days post-insertion — the insertion window. After 20 days, PID risk returns to background population levels. Pre-insertion STI screening (for Chlamydia trachomatis and Neisseria gonorrhoeae) significantly reduces this risk. Established PID requires IUD removal and antibiotic treatment.
• Ectopic pregnancy: If the IUD fails (rare), the probability that the pregnancy is ectopic is higher than in non-contraceptive users, because the IUD preferentially prevents intrauterine implantation. Women with a suspected IUD failure should have an urgent ectopic pregnancy excluded.
• Copper IUD — menstrual changes: Increased blood loss and worsening dysmenorrhoea affect 15-20% of copper IUD users sufficiently to request removal. NSAIDs reduce menstrual pain and may moderately reduce blood loss.
• LNG-IUS — irregular bleeding: Unpredictable spotting and light bleeding are common in the first 3-6 months of use. Women should be counselled about this expected pattern before insertion.

After IUD insertion, a structured follow-up plan ensures correct placement, allows detection of early complications, and addresses concerns about menstrual changes.

Immediately Post-Insertion (Hours 0-24)

• Mild to moderate cramping is expected and normal for several hours after insertion. Rest is recommended if cramping is significant.
• Ibuprofen 400 mg or paracetamol may be taken as needed for post-procedural pain
• Sanitary pads (not tampons) should be used for any spotting in the first 24 hours
• Avoid sexual intercourse, swimming pools, and tampon use for 24 hours to reduce early infection risk
• The copper IUD is immediately effective; the LNG-IUS is immediately effective if inserted within the first 7 days of the menstrual cycle, or after 7 days for all other timing

First Follow-Up (4 to 6 Weeks)

• A routine follow-up appointment at 4-6 weeks is recommended to confirm correct IUD placement by checking the retrieval strings are visible at the cervix
• Ultrasound assessment if strings are not visible or if the patient reports symptoms suggesting expulsion (sudden loss of cramping, inability to feel strings)
• Review of menstrual pattern changes — particularly important for LNG-IUS users experiencing irregular bleeding, and copper IUD users with heavy periods
• Pregnancy test if clinically indicated (missed period with unreliable string check)

Ongoing Monitoring

• Annual check: Annual string check during routine gynaecology review or sexual health appointment. Patients can also be taught to self-check strings monthly.
• IUD replacement: Device should be replaced at the end of its licensed duration (3, 5, or 10 years depending on device) unless the patient wishes to change method. In women aged 40+ using the copper Paragard, the IUD may be retained until confirmed menopause.
• STI screening: Women at ongoing STI risk should be screened periodically regardless of IUD use.

The total cost of IUD insertion encompasses the device itself, the insertion procedure, and any follow-up appointments. Costs vary substantially by country, healthcare system, and provider type.

Device Costs

• Copper IUD (Paragard): Device alone costs approximately USD 800-1,000 in the USA without insurance; significantly less in other countries
• LNG-IUS (Mirena, Kyleena, Jaydess): Device costs USD 900-1,200 in the USA; EUR 150-300 in Europe

Total Insertion Cost by Country

• USA (without insurance): USD 500-1,300 total including device and insertion; most insurance plans and Medicaid cover IUDs at no cost as preventive care under ACA provisions
• UK (NHS): Free of charge — IUD insertion is fully funded under the NHS contraceptive service
• Australia (with Medicare): The device is available through the PBS for approximately AUD 30-50; insertion is covered under Medicare
• India: Copper IUDs (Cu-T 380A) are available free of charge through the National Family Planning Programme at government facilities; private clinic insertion costs INR 2,000-8,000 (USD 24-100)
• Europe (various): Device costs EUR 150-400; insertion EUR 50-200 in private practice; publicly funded in most national health systems

Cost-Effectiveness Perspective

Despite higher upfront costs compared to monthly oral contraceptives, IUDs are among the most cost-effective contraceptive methods when amortised over their duration of use. A 10-year copper IUD in the USA costs approximately USD 100-130 per year of contraception — far less than the annual cost of oral contraceptive pills (USD 100-600 per year out-of-pocket) or injectable contraceptives. For healthcare systems, LARC methods substantially reduce unintended pregnancy rates and downstream costs.

The choice of contraceptive method is highly individual, depending on effectiveness requirements, health history, fertility plans, and personal preference. Alternatives to the IUD within the LARC category and broader contraceptive range include:

• Subdermal contraceptive implant (Nexplanon, Implanon): A single matchstick-sized rod containing etonogestrel inserted under the skin of the upper arm. Provides 3 years of highly effective contraception (failure rate <0.1%). Like the LNG-IUS, it causes menstrual irregularity in many users. Insertion and removal are simpler than IUD in outpatient settings. A good alternative for women who cannot undergo intrauterine procedures (e.g., significant uterine anomaly).
• Combined oral contraceptive pill (COCP): Daily pill containing oestrogen and progestogen. Highly effective with perfect use (failure rate 0.3%) but typical use failure rate is 7-9% due to compliance. Non-contraceptive benefits include dysmenorrhoea relief, regulated periods, and potential reduction of ovarian and endometrial cancer risk. Contraindicated in women with thromboembolic history, migraine with aura, or smokers over 35.
• Progestogen-only pill (POP/mini-pill): Daily pill containing only progestogen; suitable for women in whom oestrogen is contraindicated. Newer desogestrel-containing POPs suppress ovulation in most cycles. Requires strict daily timing compliance.
• Contraceptive injection (Depo-Provera, DMPA): Medroxyprogesterone acetate injection given every 12 weeks. Highly effective; suitable for women with compliance difficulties. Side effects include irregular bleeding and a potentially prolonged return to fertility (median 9-10 months) after discontinuation — an important consideration for women planning pregnancy soon.
• Barrier methods (male condoms, diaphragm, cap): Provide STI protection (condoms) but lower effectiveness than LARCs with typical use. Appropriate for occasional contraceptive need, STI prevention, or as adjunct protection.
• Female sterilisation (tubal ligation) or male sterilisation (vasectomy): Permanent methods recommended only for those certain they do not wish future pregnancy. Tubal ligation is a surgical procedure under general anaesthesia; vasectomy is a simpler outpatient procedure.
• Emergency contraceptive pills (levonorgestrel EC, ulipristal acetate — ellaOne): Post-coital options taken orally; appropriate for occasional use but less effective than the copper IUD for emergency contraception and not suitable for ongoing protection.